Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
OnKure Therapeutics (OKUR)
NASDAQ:OKUR
Holding OKUR?
Track your performance easily
OKUR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$9.54 - $20.00
Previous Close$9.86
Volume176.50K
Average Volume (3M)63.32K
Market Cap
$124.76M
Enterprise Value$48.75M
Total Cash (Recent Filing)$76.67M
Total Debt (Recent Filing)$665.00K
Price to Earnings (P/E)―
Beta<0.01
Next Earnings
Mar 26, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-16.85
Shares Outstanding13,339,417
10 Day Avg. Volume93,764
30 Day Avg. Volume63,324
Standard Deviation0.29
R-Squared0.00062
Alpha-0.00892
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)1.78
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-14.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.27
Forecast
1Y Price Target
$34.75Price Target Upside282.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
OnKure Therapeutics News
PremiumCompany Announcements
OnKure Therapeutics Advances Cancer Drug Trials
PremiumCompany Announcements
OnKure Therapeutics Reports Strategic Merger and Financial Updates
Bulls Say, Bears Say
Bulls Say
Clinical ProgressOnKure's lead candidate is OKI-219, a mutant-selective PI3Kα inhibitor, which is in Phase 1 for the treatment of solid tumors, with initial results expected at the upcoming SABCS annual meeting.
Drug DevelopmentOKUR is leveraging an expertise in targeted drug discovery to develop a platform of highly targeted PI3Kα agents that are more potent at relevant oncogenic mutations, while sparing normal tissues.
Financial PerformanceOKUR's peak sales for '219 in breast cancer are projected at $1.4bn, which represents $30/share in the model.
Bears Say
Clinical TrialsNegative clinical results with the lead asset, OKI-219, pose significant risks to the stock's future performance.
Competitive LandscapeThe stock faces competitive risks, particularly with other mutant-selective PI3Kα inhibitors, potentially affecting its market position.
Regulatory ApprovalsThere is a risk of delays in advancing pipeline candidates into registrational programs and obtaining regulatory approvals, which could impact the stock's valuation.
---
Ownership Overview
8.71% Insiders
0.17% Mutual Funds
0.03% Other Institutional Investors
89.80% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
OKUR FAQ
What was OnKure Therapeutics’s price range in the past 12 months?
OnKure Therapeutics lowest stock price was $9.54 and its highest was $20.00 in the past 12 months.
What is OnKure Therapeutics’s market cap?
Currently, no data Available
When is OnKure Therapeutics’s upcoming earnings report date?
OnKure Therapeutics’s upcoming earnings report date is Mar 26, 2025 which is in 86 days.
How were OnKure Therapeutics’s earnings last quarter?
Currently, no data Available
Is OnKure Therapeutics overvalued?
According to Wall Street analysts OnKure Therapeutics’s price is currently Undervalued.
Does OnKure Therapeutics pay dividends?
OnKure Therapeutics does not currently pay dividends.
What is OnKure Therapeutics’s EPS estimate?
OnKure Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OnKure Therapeutics have?
OnKure Therapeutics has 12,652,890 shares outstanding.
What happened to OnKure Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of OnKure Therapeutics?
Among the largest hedge funds holding OnKure Therapeutics’s share is Highbridge Capital Management LLC. It holds OnKure Therapeutics’s shares valued at 5M.
---
OnKure Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.75 (282.71% Upside)
$34.75 (282.71% Upside)
Hedge Fund Trend
Decreased
By 73.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $703.4K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-87.27%
12-Months-Change
Fundamentals
Return on Equity
-54.00%
Trailing 12-Months
Asset Growth
-46.83%
Trailing 12-Months
Company Description
OnKure Therapeutics
Reneo Pharmaceuticals Inc is a clinical stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.
---
OKUR Stock 12 Month Forecast
Average Price Target
$34.75
▲(282.71% Upside)
Technical Analysis
Foghorn Therapeutics
―
Heron Therapeutics
―
Seres Therapeutics
―
Praxis Precision Medicines
―
Best Analysts Covering OKUR
1 Year
1 Year Success Rate
2/4 ratings generated profit
1 Year Average Return
-23.90%
reiterated a sell rating 9 months ago
Copying Jason Zemansky's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -23.90% per trade.
---